Maxim Group analyst Naz Rahman maintained a Buy rating on Vivani Medical (VANI – Research Report) yesterday. The company’s shares closed yesterday at $2.21.
Rahman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Petros Pharmaceuticals, and Agile Therapeutics. According to TipRanks, Rahman has an average return of 0.1% and a 35.26% success rate on recommended stocks.
Vivani Medical has an analyst consensus of Moderate Buy.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $7.80 and a one-year low of $0.75. Currently, Vivani Medical has an average volume of 3.14M.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VANI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vivani Medical (VANI) Company Description:
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. Its product, the Argus II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
Read More on VANI:
